Professor Richard Scolyer, a leading melanoma pathologist and the 2024 Australian of the Year, died in Australia on June 8, 2026 [1].
Scolyer's death marks the loss of a world-renowned researcher who spent his final years attempting to revolutionize the treatment of aggressive brain tumors. His willingness to undergo experimental procedures on himself provided critical data for the global medical community.
Scolyer died at age 59 [1] following a three-year battle with glioblastoma [2]. Glioblastoma is characterized as an aggressive form of brain cancer [1]. Throughout his illness, Scolyer remained active in the scientific community, treating his own diagnosis as a clinical opportunity to advance oncology.
He became the first patient worldwide to receive a specific combination of three immunotherapy drugs before the surgical removal of his tumor [1]. This pioneering approach sought to prime the immune system to recognize and attack cancer cells before the physical extraction of the mass.
In a final message, Scolyer encouraged others to "pursue their dreams and passion with humility, love, and compassion" [1]. Colleagues noted the impact of his contributions to the field of pathology and immunotherapy.
"The field owes him a great debt of gratitude," a colleague said [1].
Scolyer's work focused heavily on melanoma and brain cancer, utilizing his position as a pathologist to bridge the gap between laboratory research and patient bedside care. His legacy includes the development of immunotherapy protocols that aim to extend survival rates for patients facing the most aggressive malignancies [2].
“The field owes him a great debt of gratitude.”
Scolyer's decision to act as the primary subject for a triple-immunotherapy regimen represents a rare instance of a high-profile researcher utilizing their own terminal diagnosis to test a novel hypothesis. While the treatment did not save his life, the data gathered from his case may refine the timing and combination of immunotherapy drugs used in glioblastoma treatment, potentially shifting the standard of care for future patients.
